Abstract #3864
Predicting Response to Sunitinib Second-line Therapy in Gastrointestinal Stromal Tumors Using Non-Gaussian Diffusion MRI
Yi Sui 1,2 , Lei Tang 3 , Kejia Cai 2,4 , Shun-Yu Gao 3 , Frederick C. Damen 2,4 , Ying-Shi Sun 3 , and Xiaohong Joe Zhou 2,5
1
Bioengineering, University of Illinois at
Chicago, Chicago, IL, United States,
2
Center
for MR Research, University of Illinois Hospital &
Health Sciences System, Chicago, IL, United States,
3
Radiology,
Peking University Cancer Hospital & Institute, Beijing,
China,
4
Radiology,
University of Illinois Hospital & Health Sciences
System, Chicago, IL, United States,
5
Departments
of Radiology, Neurosurgery and Bioengineering,
University of Illinois Hospital & Health Sciences
System, Chicago, IL, United States
Sunitinib offers a second line treatment to
gastrointestinal stromal tumor (GIST) patients with
imatinib-resistant progressive lesions. Prediction of
the treatment response is crucial for achieving optimal
outcomes. We used a non-Gaussian diffusion model, known
as the fractional order calculus model (FROC), to assess
the early response to sunitinib treatment in
imatinib-resistant GIST lesions. Our results showed that
the FROC model outperformed the conventional means of
using tumor size in predicting tumor response at as
early as 2 weeks after receiving sunitinib treatment.
This study suggests that non-Gaussian diffusion imaging
can provide timely information to evaluate sunitinib
targeted therapy of GIST.
This abstract and the presentation materials are available to members only;
a login is required.
Join Here
